The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
This has been a game-changer for my weight loss journey
The clinical indications are critically examined, encompassing its limited utility in refractory essential hypertension, its designated role in hypertensive emergencies of pregnancy, and its evidence-based application in combination with isosorbide dinitrate for heart failure with reduced ejection fraction, particularly within the African American population
Use data to understand the current and forecasted demand for GLP-1s among your members to determine the potential benefits and costs for your plan
Similar benefits are seen in overweight and obese patients with diabetes mellitus [25]
